Ikaros expression and association with other prognostic markers of chronic lymphocytic leukemia

• Grant number: 14/26596-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: March 01, 2015
• End date: February 29, 2016
• Field of knowledge: Biological Sciences - Immunology
• Principal Investigator: Ana Flavia Popi
• Grantee: Bárbara Bomfim Muniz Moraes
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

Chronic Lymphocytic leukemia (CLL) is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Ikaros is considered an important regulator of lymphoid development and differentiation. Several reports reinforce the hypothesis that Ikaros expression is deregulated in human leukemias. Patients with CLL can be categorized in 2 subsets on the basis of immunoglobulin heavy chain variable region (IGHV) gene mutation status. The expression of zap-70 and some recurrent genomic alterations are also prognostic markers. Considering this, herein we purpose to investigate the expression of Ikaros in the B-CLL, and also correlate those prognostic factors to Ikaros expression.